Next Article in Journal
Immunomodulatory Effects of TGF-β Family Signaling within Intestinal Epithelial Cells and Carcinomas
Next Article in Special Issue
Sarcopenia as a Risk Factor of Morbimortality in Colorectal Cancer Surgery
Previous Article in Journal / Special Issue
Bifidobacteria and Mucosal-Associated Invariant T (MAIT) Cells: A New Approach to Colorectal Cancer Prevention?
Open AccessReview

Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs

1
Department of Gastroenterology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
2
Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
*
Author to whom correspondence should be addressed.
Gastrointest. Disord. 2019, 1(2), 273-289; https://doi.org/10.3390/gidisord1020023
Received: 20 May 2019 / Revised: 10 June 2019 / Accepted: 11 June 2019 / Published: 12 June 2019
(This article belongs to the Special Issue Colorectal Cancer: Biology and Therapy)
The global deaths due to colorectal cancer and diabetes mellitus have increased by 57% and 90%, respectively. The relationship between various cancers and diabetes mellitus has been shown in multiple epidemiological studies. Hence, better management of diabetes mellitus is expected to reduce the risk of various cancers. This review focuses on colorectal cancer and aims to summarize recent findings on the antitumor effects of various oral hypoglycemic drugs on colorectal cancer and their estimated mechanisms. Of the seven classes of oral hypoglycemic agents, only metformin was found to have suppressive effects on colorectal cancer in both clinical and basic research. Clinical and basic researches on suppressing effects of glinides, dipeptidyl peptidase-4 inhibitors, thiazolidinedione, α-glucosidase inhibitors, and sodium glucose cotransporter-2 inhibitors against colon carcinogenesis have been insufficient and have not arrived at any conclusion. Therefore, further research regarding these agents is warranted. In addition, the suppressive effects of these agents in healthy subjects without diabetes should also be investigated. View Full-Text
Keywords: colorectal cancer; diabetes mellitus; metformin; alpha-glucosidase inhibitors; SGLT2 inhibitors; insulin-like growth factor colorectal cancer; diabetes mellitus; metformin; alpha-glucosidase inhibitors; SGLT2 inhibitors; insulin-like growth factor
Show Figures

Figure 1

MDPI and ACS Style

Kato, J.; Shirakami, Y.; Shimizu, M. Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs. Gastrointest. Disord. 2019, 1, 273-289.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Back to TopTop